UPDATE: Immunomedics Announces Termination of Agreement and Return of Worldwide Rights to Veltuzumab for All Non-Cancer Indications

Immunomedics (Nasdaq: IMMU ), a biopharmaceutical company primarily focused on the development of monoclonal antibody-based products for the targeted treatment of cancer, autoimmune and other serious diseases, today announced that the Company has received notification from Takeda Pharmaceutical Company of the termination of the licensing agreement signed between Nycomed GmbH and Immunomedics for the worldwide